Riskpilot← Back to searchSign inGet full accessZinnoSci AB
ABActiveOrg 5592751977Per Eskils Gata 19Hospital activities · NACE 8610Est. 20200 employees
Revenue 2025
SEK 144K
-47% vs 2024
EBITDA margin
86.7%
-50% vs 2024
Equity ratio
57.0%
Financial strength
Net profit 2025
SEK 100K
-51% vs 2024
| Revenue | SEK 144K | -47% |
| EBITDA | SEK 125K | -50% |
| Net profit | SEK 100K | -51% |
| Total assets | SEK 223K | -32% |
| Equity | SEK 127K | -44% |
| Employees | 0 | — |
Legal name
ZinnoSci AB
Org number
5592751977
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
6 oktober 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultuppdrag som läkare inom primärvård, digital sjukvård, akutsjukvård samt anestesi och intensivvård. Konsultuppdrag som utbildare inom medicinska ämnen, föreläsare och konferencier. Innovation och utveckling av produkter inom och utanför sjukvården. Utveckling av mobilappar. Förvaltning och ägande utav fast och lös egendom.
Address
Per Eskils Gata 19
Email
markozindovic89@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | — | 495 | 272 | 144 |
| Staff expenses | — | — | −6 | −3 | −2 |
| EBITDA | −6 | 0 | 472 | 248 | 125 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −6 | 0 | 472 | 248 | 125 |
| Net financials | — | — | 0 | 7 | 1 |
| Profit before tax | −6 | 0 | 473 | 255 | 126 |
| Tax | −0 | — | −97 | −52 | −26 |
| Net profit | −6 | — | 375 | 202 | 100 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 19 | — | 597 | 330 | 223 |
| Equity | 19 | — | 390 | 228 | 127 |
| Long-term debt | 0 | — | 1 | 0 | 0 |
| Short-term debt | 0 | — | 206 | 102 | 96 |
| Total debt | — | — | 207 | 102 | 96 |
EBITDA margin
86.7%
This company
15.8%
Market median
+449% vs market
20212025
Equity ratio
57.0%
This company
38.2%
Market median
+49% vs market
20212025
Return on equity
78.3%
This company
18.4%
Market median
+326% vs market
20212025
Net profit margin
69.1%
This company
8.1%
Market median
+753% vs market
20212025
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
20212025
Debt / equity
0.75×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZinnoSci AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Igor Zindovic | Deputy Board Member | 0 companies |
| Marko Zindovic | Board of Directors | 0 companies |
| Sandra Anna Kristina Niklasson | Deputy Board Member | 0 companies |